ReviewBiology direct2020
Cancer predictive studies.
Review in Biology direct, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Therapeutic Strategies and Oncological Outcome of Peritoneal Metastases from Lung Cancer: A Systematic Review and Pooled Analysis.Current oncology (Toronto, Ont.) · 2023Pooled it
- Gastrointestinal functions after laparoscopic right colectomy with intracorporeal anastomosis: a pilot randomized clinical trial on effects of abdominal drain, prolonged antibiotic prophylaxis, and D3 lymphadenectomy with complete mesocolic excision.International journal of colorectal disease · 2024Trial
- Paired-Box (PAX) Gene Signatures as a Biomarker of Breast Cancer Progression.International journal of molecular sciences · 2026Article
- Multi-omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine.Molecular oncology · 2025Article
- PAX Family, Master Regulator in Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- Implications of Mineralization Biomarkers in Breast Cancer Outcomes Beyond Calcifications.International journal of molecular sciences · 2025Article
- Impact of the environmental pollution on cardiovascular diseases: From epidemiological to molecular evidence.Heliyon · 2024Review
- Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype.Discover oncology · 2024Article
- A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient.Cell death discovery · 2023Article
- BUN level is associated with cancer prevalence.European journal of medical research · 2023Article
- Healthy lifestyle? or just the right genetic mutations.Cell cycle (Georgetown, Tex.) · 2023Article
- ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer.International journal of molecular sciences · 2023Article
- Gene expression in organoids: an expanding horizon.Biology direct · 2023Review
- Influence of COVID-19 Pandemic on Colorectal Cancer Presentation, Management and Outcome during the COVID-19 Pandemic.Journal of clinical medicine · 2023Article
- Article
- BAP1 in cancer: epigenetic stability and genome integrity.Discover oncology · 2022Review
- Benefits of minimally invasive surgery in the treatment of gastric cancer.World journal of gastroenterology · 2022Article
- Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview.Biology direct · 2022Review
- Targeting lipid metabolism in cancer: neuroblastoma.Cancer metastasis reviews · 2022Review
- No Time to Die: How Kidney Cancer Evades Cell Death.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 3 countries.
Funding
Abstract
The identification of individual or clusters of predictive genetic alterations might help in defining the outcome of cancer treatment, allowing for the stratification of patients into distinct cohorts for selective therapeutic protocols. Neuroblastoma (NB) is the most common extracranial childhood tumour, clinically defined in five distinct stages (1-4 & 4S), where stages 3-4 define chemotherapy-resistant, highly aggressive disease phases. NB is a model for geneticists and molecular biologists to classify genetic abnormalities and identify causative disease genes. Despite highly intensive basic research, improvements on clinical outcome have been predominantly observed for less aggressive cancers, that is stages 1,2 and 4S. Therefore, stages 3-4 NB are still complicated at the therapeutic level and require more intense fundamental research. Using neuroblastoma as a model system, here we herein outline how cancer prediction studies can help at steering preclinical and clinical research toward the identification and exploitation of specific genetic landscape. This might result in maximising the therapeutic success and minimizing harmful effects in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.